The NY Times reports that a federal judge on Monday struck down patents on two genes linked to breast and ovarian cancer. The decision, if upheld, could throw into doubt the patents covering thousands of human genes and reshape the law of intellectual property.
U.S. Judge Invalidates Human Gene Patent
2 Comments
Recent Posts
Government Enacts Political Party Anti-Privacy Rules With Bill C-4 Royal Assent Sprint 
A Tale of Two Bills: Lawful Access Returns With Changes to Warrantless Access But Dangerous Backdoor Surveillance Risks Remain 
Words Are Not Enough: Countering Relentless Antisemitic Violence in Canada With Action 
The Law Bytes Podcast, Episode 260: What the Government Didn’t Want You To Hear About Bill C-4 And Its Weak Political Party Privacy Rules 
Why the Online Harms Act is the Wrong Way to Regulate AI Chatbots
“Myriad Genetics, the company that holds the patents with the University of Utah Research Foundation, asked the court to dismiss the case, claiming that the work of isolating the DNA from the body transforms it and makes it patentable. ”
So, they claim they aren’t actually patenting the two genes, they are patenting transformed version of the genes? To me this would invalidate the work of the human genome project, as they cataloged not the human genome but some variation thereof… Or am I understanding the claim incorrectly?
They’re claiming that isolated DNA is “transformed”, so the not-found-in-nature requirement of a patent doesn’t apply to the genes.